6661.Two
6661.TWO is a healthcare diagnostics company that generates revenue primarily through the development and sale of diagnostic products and services.
Business. 6661.TWO is a healthcare diagnostics company that generates revenue primarily through the development and sale of diagnostic products and services.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
6661.TWO is a healthcare diagnostics company that generates revenue primarily through the development and sale of diagnostic products and services.
6661.TWO has a market capitalization of TWD 410.15 million and a price-to-earnings ratio of 308.38, indicating a high valuation relative to its earnings. The company's liquidity position is characterized as medium, with a current ratio of 2.21, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's free cash flow is negative at TWD -12.95 million, and capital expenditures are TWD -42.04 million, indicating significant investment in long-term assets.
Profitability metrics for 6661.TWO are modest, with a return on equity of 0.47% and a return on assets of 0.21%, both below the typical thresholds for strong performance in the biotechnology and medical research industry. The company's operating income is TWD 127,000, and net income is TWD 1.33 million, which is a small fraction of its revenue of TWD 375.94 million. The gross profit margin is 41.55%, which is relatively healthy but not exceptional for the industry.
The company's revenue is not segmented by geographic regions or product lines in the provided data, so it is not possible to assess geographic or segment concentration. However, the company's total assets amount to TWD 622.19 million, with total liabilities of TWD 340.89 million and total equity of TWD 281.29 million. The debt-to-equity ratio is 0.8, indicating a moderate level of leverage.
Looking at the company's growth trajectory, there is no specific data provided on revenue growth or future projections. The company's operating cash flow is TWD 35.27 million, which is positive but not sufficient to cover the capital expenditures. The company's long-term debt is TWD 226.03 million, which is a significant portion of its total liabilities.
The risk assessment for 6661.TWO indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose a challenge in maintaining liquidity. There are no specific dilution sources mentioned in the provided data, and the dilution potential is assessed as low.
Recent events or filings that could impact the company's performance are not detailed in the provided data. The company's financial health and strategic direction would benefit from more detailed disclosures on its recent activities and future plans.
- 6661.TWO has a high price-to-earnings ratio, indicating a premium valuation relative to its earnings.
- The company's liquidity position is moderate, with a current ratio of 2.21.
- Profitability metrics are weak, with a return on equity of 0.47% and a return on assets of 0.21%.
- The company has a significant amount of long-term debt, which could impact its financial flexibility.
- There is no detailed information on geographic or segment revenue concentration, limiting the assessment of diversification risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 6661.TWO Market data — financials · 2026-05-27